Trade

with

Omeros Corp
(NASDAQ: OMER)
AdChoices
13.25
-0.53
-3.85%
After Hours :
13.25
0.00
0.00%

Open

13.77

Previous Close

13.78

Volume (Avg)

321.94k (282.67k)

Day's Range

13.10-13.92

52Wk Range

6.92-18.80

Market Cap.

450.44M

Dividend Rate ( Yield )

-

Beta

1.12

Shares Outstanding

34.00M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.60M

    • Net Income

    • -39.80M

    • Market Cap.

    • 450.44M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -9,872.16

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.12

    • Forward P/E

    • -38.46

    • Price/Sales

    • 833.33

    • Price/Book Value

    • -42.37

    • Price/Cash flow

    • -10.96

      • EBITDA

      • -37.13M

      • Return on Capital %

      • -157.21

      • Return on Equity %

      • -

      • Return on Assets %

      • -157.21

      • Book Value/Share

      • -0.31

      • Shares Outstanding

      • 34.00M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 34.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -67.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 6.46

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -9,872.16

            • 39.38

            • Net Profit Margin

            • -9,872.16

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,321.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.20

              • 2.92

              • Quick Ratio

              • 3.10

              • 2.35

              • Interest Coverage

              • -16.98

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.31

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.22

                • 188.68

                • P/E Ratio 5-Year High

                • -11.67

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.96

                • 124.82

                • Price/Sales Ratio

                • 833.33

                • 8.72

                • Price/Book Value

                • -42.37

                • 7.95

                • Price/Cash Flow Ratio

                • -10.96

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -157.21

                    (-102.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.02

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -50.52M
                  Operating Margin
                  -3,157.25
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -10.96
                  Ownership

                  Institutional Ownership

                  46.40%

                  Top 10 Institutions

                  31.12%

                  Mutual Fund Ownership

                  16.40%

                  Float

                  93.16%

                  5% / Insider Ownership

                  5.85%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • SPDR® S&P Pharmaceuticals ETF

                  •  

                    761,827

                  • 0.00

                  • 2.43

                  • iShares Russell 2000 (AU)

                  •  

                    534,317

                  • 3.56

                  • 1.70

                  • Vanguard Total Stock Mkt Idx

                  •  

                    517,793

                  • 0.00

                  • 1.52

                  • iShares Nasdaq Biotechnology

                  •  

                    440,845

                  • 0.24

                  • 1.40

                  • Candriam Eqs L Biotechnology

                  •  

                    415,000

                  • -7.37

                  • 1.22

                  • Vanguard Extended Market Index Fund

                  •  

                    294,192

                  • 2.64

                  • 0.87

                  • iShares Russell 2000 Growth

                  •  

                    231,493

                  • 1.33

                  • 0.74

                  • Tocqueville Fund

                  •  

                    175,000

                  • 16.67

                  • 0.51

                  • Mutual of America Small Cap Growth

                  •  

                    133,589

                  • -6.33

                  • 0.39

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    108,585

                  • 0.00

                  • 0.32

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Ingalls & Snyder LLC

                  •  

                    2,066,279

                  • +16.88%

                  • 6.08

                  • Tocqueville Asset Management L.P.

                  •  

                    1,518,989

                  • +20.09%

                  • 4.47

                  • BlackRock Fund Advisors

                  •  

                    1,249,271

                  • -4.37%

                  • 3.67

                  • Cormorant Asset Management, LLC

                  •  

                    1,123,000

                  • +124.60%

                  • 3.30

                  • Vanguard Group, Inc.

                  •  

                    938,532

                  • +1.74%

                  • 2.76

                  • Baker Bros Advisors LLC

                  •  

                    753,804

                  • 0.00%

                  • 2.22

                  • State Street Corp

                  •  

                    466,906

                  • +5.57%

                  • 1.37

                  • Candriam Luxembourg

                  •  

                    415,000

                  • -7.37%

                  • 1.22

                  • Northern Trust Investments, N.A.

                  •  

                    379,680

                  • -3.50%

                  • 1.12

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 c...morelinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in December 2013, the EMA accepted Omidria as the proposed brand name for OMS302 in the EU. In addition to Omidria, the Company has other development programs for pain, inflammation, coagulopathies and disorders of the ...morecentral nervous system. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPAR? program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPAR? agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. As of February 15, 2014, the Company owned or held licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets. The Company is subject to regulate under the U.S. and EU governing regulations.lessless

                  Key People

                  Dr. Gregory A. Demopulos,M.D.

                  CEO/Chairman of the Board/Director/Founder/President

                  Mr. Michael Jacobsen

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Timothy M. Duffy

                  Vice President, Divisional

                  Michael K. Inouye

                  Vice President, Divisional

                  Ms. Marcia S. Kelbon

                  General Counsel/Secretary/Vice President, Divisional

                  • Omeros Corp

                  • 201 Elliott Avenue West

                  • Seattle, WA 98119

                  • USA.Map

                  • Phone: +1 206 676-5000

                  • Fax: -

                  • omeros.com

                  Incorporated

                  1994

                  Employees

                  75

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: